| 7.02 0 (0%) | 04-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.21 | 1-year : | 9.59 |
| Resists | First : | 7.03 | Second : | 8.21 |
| Pivot price | 7  |
|||
| Supports | First : | 6.98 | Second : | 6.94 |
| MAs | MA(5) : | 7.01 |
MA(20) : | 6.99 |
| MA(100) : | 5.64 |
MA(250) : | 5.33 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.6 |
D(3) : | 80.3 |
| RSI | RSI(14): 70.6 | |||
| 52-week | High : | 9.67 | Low : | 3.07 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACCD ] has closed below upper band by 14.6%. Bollinger Bands are 94.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.03 - 7.06 | 7.06 - 7.09 |
| Low: | 6.93 - 6.97 | 6.97 - 7.01 |
| Close: | 6.96 - 7.02 | 7.02 - 7.07 |
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Tue, 08 Apr 2025
Accolade completes merger with Transcarent, shifts control - Investing.com
Tue, 08 Apr 2025
Healthcare Giant Emerges: Transcarent-Accolade Merger Creates AI-Powered Platform Serving 20M Members - Stock Titan
Thu, 27 Mar 2025
Accolade Stockholders Approve Merger Between Accolade and Transcarent - GlobeNewswire
Wed, 26 Mar 2025
Is Accolade Inc. (NASDAQ:ACCD) the Best Performing Stock So Far In 2025? - Yahoo Finance
Thu, 06 Mar 2025
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem - PR Newswire
Mon, 03 Feb 2025
Why Accolade Inc (ACCD) Is Skyrocketing So Far In 2025 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 82 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 88.1 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 2,000 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.85 |
| Profit Margin | -40.4 % |
| Operating Margin | -22.8 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -48.3 % |
| Qtrly Rev. Growth | 5.6 % |
| Gross Profit (p.s.) | 2.62 |
| Sales Per Share | 5.44 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 22 (M) |
| PE Ratio | -3.08 |
| PEG Ratio | 0 |
| Price to Book value | 1.81 |
| Price to Sales | 1.28 |
| Price to Cash Flow | -85.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|